title: Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer.
authors.affiliation: Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada. Electronic address: ian.tannock@uhn.ca.
authors.forename: I F
authors.initials: IF
authors.lastname: Tannock
authors.affiliation: Ontario Clinical Oncology Group, McMaster University, Hamilton, Canada.
authors.forename: G R
authors.initials: GR
authors.lastname: Pond
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D020123:Sirolimus